Serplulimab with chemotherapy in extensive-stage SCLC Editorial

  

Authors:	Choudhury, N. J.; Riely, G. J.
Title:	Serplulimab with chemotherapy in extensive-stage SCLC
Keywords:	cancer chemotherapy; cancer survival; treatment response; unclassified drug; overall survival; cigarette smoking; drug approval; cancer patient; cancer staging; antineoplastic agent; cancer diagnosis; clinical practice; carboplatin; cancer immunotherapy; progression free survival; antineoplastic metal complex; etoposide; antineoplastic combined chemotherapy protocols; lung neoplasms; prevalence; editorial; food and drug administration; lung tumor; survival time; disease severity; protein inhibitor; small cell lung cancer; small cell lung carcinoma; clinical outcome; passive smoking; programmed death 1 ligand 1 antibody; programmed death 1 receptor antibody; immune checkpoint inhibitor; humans; human; pembrolizumab; durvalumab; atezolizumab; immunological antineoplastic agent; serplulimab
Journal Title:	JAMA - Journal of the American Medical Association
Volume:	328
Issue:	12
ISSN:	0098-7484
Publisher:	American Medical Association
Date Published:	2022-09-27
Start Page:	1205
End Page:	1207
Language:	English
DOI:	10.1001/jama.2022.16442
PUBMED:	36166047
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139165814&doi=10.1001%2fjama.2022.16442&partnerID=40&md5=e5dc5033130b2c656cb7244547a1d43d
Notes:	Editorial -- Export Date: 1 November 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/199162